• Revance To Acquire HintMD

    1 month ago - By Surgical Aesthetics Magazine

    Revance Therapeutics, a biotechnology company focused on aesthetic and therapeutic offerings including a next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, has signed a definitive agreement to acquire Hint, a privately held company doing business under the name HintMD, which has created an integrated financial technology platform for the aesthetics industry. The transaction is expected to close in the third quarter of 2020, subject to customary closing conditions, including receipt of approval of the requisite HintMD stockholders.
    In addition to credit card...
    Read more ...